Literature DB >> 23245422

Misoprostol and the politics of abortion in Sri Lanka.

Ramya Kumar1.   

Abstract

Misoprostol, a WHO essential medicine indicated for labour induction, management of miscarriage and post-partum haemorrhage, as well as for induced abortion and treatment of post-abortion complications, came up for registration in Sri Lanka in December 2010. The decision on registration was postponed, indefinitely. This has wide-ranging implications, as misoprostol is widely available and used, including by health professionals in Sri Lanka, without guidance or training in its use. This paper attempts to situate the failure to register misoprostol within the broader context of unsafe abortion, drawing on data from interviews with physicians and health policymakers in Sri Lanka. It demonstrates how personal opposition to abortion infiltrates policy decisions and prevents the issue of unsafe abortion being resolved. Any move to reform abortion law and policy in Sri Lanka will require a concerted effort, spearheaded by civil society. Women and communities affected by the consequences of unsafe abortion need to be involved in these efforts. Regardless of the law, women will access abortion services if they need them, and providers will provide them. Decriminalizing abortion and registering abortion medications will make provision of abortion services safer, less expensive and more equitable.
Copyright © 2012 Reproductive Health Matters. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245422     DOI: 10.1016/S0968-8080(12)40652-8

Source DB:  PubMed          Journal:  Reprod Health Matters        ISSN: 0968-8080


  2 in total

1.  Abortion in Sri Lanka: the double standard.

Authors:  Ramya Kumar
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

2.  The politics of unsafe abortion in Burkina Faso: the interface of local norms and global public health practice.

Authors:  Katerini T Storeng; Fatoumata Ouattara
Journal:  Glob Public Health       Date:  2014-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.